

Dated: 16th December 2022

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

**Shilpa Medicare Limited- Launch of Shilpa’s new brand Capebel
(Capecitabine 1000 MG dispersible tablet)**

Shilpa Medicare Ltd, a Raichur (Karnataka) based pharmaceutical company, dedicated in providing world class Oncology and Non-Oncological products to patients across the geographies, announces yet another innovation in treatment of Colorectal and Metastatic Breast Cancer. The company has introduced **Capecitabine 1000 MG dispersible tablet** for the first time in the world, with novel technology of faster dispersion within 90 seconds.

Till now Capecitabine is available in 500 mg and 150 mg tablets and the recommended doses are 3500 to 4000 mg /day divided into two doses for 14 consecutive days requiring 7 to 8 tablets to be consumed by the patients daily. This was an unmet need and remains a big issue for Cancer patients. Swallowing of 7 to 8 tablets pose a challenge in completing daily doses since most cancer patients have swallowing difficulties and hence a significant patient compliance issue.

With the revolutionary introduction of Shilpa’s new brand, “**Capebel**”, patients will be required to just drop the tablets in 100 mL water and allow the tablets to dissolve and then drink dissolved solution. Hence from 7 to 8 tablets a day, patients just need to drink 100 mL water twice daily with dissolved tablets in it.

It is expected to change the patient’s compliance and will help them continue with the correct doses with ease of drinking water and getting desired outcomes.

Shilpa Medicare Limited

Corporate & Admin Office:

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

The product is backed by required scientific proof and comparative bioequivalence studies and is approved by CDSCO. Innovation with affordability is the constant endeavor of Shilpa Medicare which has introduced many innovative formulations such as Vomistrip - the 1st Orally Disintegrating Strips (Ondansetron) for better compliance helping patients and care givers with better outcomes.

The Company has launched the product in the Indian market on 16th Dec'22 and is further looking to introduce Capebel 1 gm DT in various international markets through our partners and clients.

This is for your information and doing the needful.

For **SHILPA MEDICARE LIMITED**

RITU
TIWARY

Ritu Tiwary

Company Secretary & Compliance Officer

Digitally signed by
RITU TIWARY
Date: 2022.12.16
18:10:07 +05'30'